John Higgins Biography and Net Worth

Director of OmniAb

John Higgins served as Chief Executive Officer at Ligand Pharmaceuticals from January 2007 to December 2022. Prior to joining Ligand, Mr. Higgins served as Chief Financial Officer at Connetics Corporation (Connetics), a specialty pharmaceutical company, since 1997, and also served as Executive Vice President, Finance and Administration and Corporate Development at Connetics until its acquisition by Stiefel Laboratories, Inc. in December 2006. Before joining Connetics, he was a member of the executive management team at BioCryst Pharmaceuticals Inc. Prior to BioCryst, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. Mr. Higgins serves on the board, audit committee and nominations and governance committee of Bio-Techne Corporation, a publicly-traded life sciences services company. Mr. Higgins has served as a director on numerous public and private companies. He also serves as the chairperson of the board of trustees of Academy of Whole Learning, a non-profit organization dedicated to providing educational and therapy services to children of underrepresented communities. He graduated Magna Cum Laude from Colgate University with an A.B. in economics.

What is John L. Higgins' net worth?: The estimated net worth of John L. Higgins is at least $5.69 million as of November 6th, 2025. Higgins owns 2,888,110 shares of OmniAb stock worth more than $5,689,577 as of December 4th. This net worth approximation does not reflect any other investments that Higgins may own. Learn More about John L. Higgins' net worth.
How do I contact John L. Higgins?: The corporate mailing address for Higgins and other OmniAb executives is 65 EAST 55TH STREET 18TH FLOOR, NEW YORK NY, 10022. OmniAb can also be reached via phone at 510-250-7800 and via email at [email protected]. Learn More on John L. Higgins' contact information.
Has John L. Higgins been buying or selling shares of OmniAb?: During the last ninety days, John L. Higgins has bought $107,706.87 in shares of OmniAb stock. Most recently, on Friday, November 7th, John L. Higgins bought 41,038 shares of OmniAb stock. The stock was acquired at an average cost of $1.38 per share, with a total value of $56,632.44. Following the completion of the transaction, the director now directly owns 2,929,148 shares of the company's stock, valued at $4,042,224.24. Learn More on John L. Higgins' trading history.
Who are OmniAb's active insiders?: OmniAb's insider roster includes Charles Berkman (Insider), Matthew Foehr (President and CEO), Kurt Gustafson (CFO), John Higgins (Director), and Steven Love (Director). Learn More on OmniAb's active insiders.
Are insiders buying or selling shares of OmniAb?: In the last year, OmniAb insiders bought shares 5 times. They purchased a total of 293,011 shares worth more than $533,319.37. In the last year, insiders at the sold shares 9 times. They sold a total of 150,811 shares worth more than $458,129.12. The most recent insider tranaction occured on November, 7th when Director John L Higgins bought 41,038 shares worth more than $56,632.44. Insiders at OmniAb own 8.6% of the company. Learn More about insider trades at OmniAb.
Information on this page was last updated on 11/7/2025.

John L. Higgins Insider Trading History at OmniAb

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/7/2025	Buy	41,038	$1.38	$56,632.44	2,929,148
11/6/2025	Buy	36,223	$1.41	$51,074.43	2,888,110
5/12/2025	Buy	65,000	$1.44	$93,600.00	2,831,887
3/20/2025	Buy	125,750	$2.35	$295,512.50	2,762,887
5/23/2023	Sell	9,000	$4.05	$36,450.00	2,462,686
5/18/2023	Sell	50,000	$3.89	$194,500.00	2,462,686

John L. Higgins Buying and Selling Activity at OmniAb

OmniAb Company Overview

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

Today's Range

Now: $1.97

$1.86

$1.98

50 Day Range

MA: $1.64

$1.38

$1.97

2 Week Range

Now: $1.97

$1.22

$4.17

Volume

454,821 shs

Average Volume

503,386 shs

Market Capitalization

$283.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.13